Get the Stockscreener App
20.12
1.82%
0.36
Castle Biosciences Inc stock is traded at $20.12, with a volume of 415.21K.
It is up +1.82% in the last 24 hours and up +10.73% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
See More
Previous Close:
$19.76
Open:
$19.83
24h Volume:
415.21K
Relative Volume:
0.98
Market Cap:
$520.86M
Revenue:
$219.79M
Net Income/Loss:
$-57.47M
P/E Ratio:
-9.3581
EPS:
-2.15
Net Cash Flow:
$-19.25M
1W Performance:
+0.55%
1M Performance:
+10.73%
6M Performance:
-38.51%
1Y Performance:
+12.72%
1-Day Range:
$19.57
$20.22
1-Week Range:
$19.21
$20.52
52-Week Range:
$15.45
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Compare CSTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
20.12 | 520.86M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
419.88 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
200.96 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
540.64 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
121.30 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
162.02 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences partners with SciBase for diagnostic tests - MSN
Castle Biosciences Inc (CSTL) Stock Price Down 4.54% on Jun 17 - GuruFocus
Castle Biosciences, SciBase Partner to Develop Predictive Tests for Skin Conditions - marketscreener.com
Castle Biosciences partners with SciBase for diagnostic tests (CSTL) - Seeking Alpha
Castle Biosciences enters collaboration, license agreement with Scibase to develop diagnostic tests for dermatologic diseases - MarketScreener
SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million - Yahoo Finance
Castle Biosciences Enters Collaboration and License Agreement wi - GuruFocus
Castle Biosciences (CSTL) Partners with SciBase for Dermatology Advancements | CSTL Stock News - GuruFocus
Castle Biosciences partners with SciBase to develop atopic dermatitis test - Investing.com
SciBase signs license agreement with Castle Biosciences to develop dermatology diagnostic tests - marketscreener.com
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases - The Manila Times
Castle Biosciences Enters Collaboration and License - GlobeNewswire
New Diagnostic Test Could Predict Atopic Dermatitis Flares Before Symptoms Appear - Stock Titan
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - Barchart.com
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention | CSTL Stock News - GuruFocus
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - The Manila Times
Castle Biosciences’ Chief Executive Officer Derek Maetzold - GlobeNewswire
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion ... - Bluefield Daily Telegraph
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention - Barchart.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Two Sigma Advisers LP Acquires New Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Squarepoint Ops LLC Lowers Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards® - The Manila Times
Castle Biosciences’ Founder, President and CEO Derek - GlobeNewswire
ProShare Advisors LLC Makes New $230,000 Investment in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025 - Insider Monkey
Castle Biosciences Presents Innovative Research on Melanoma Risk Stratification at ASCO 2025 - Nasdaq
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
Man Group plc Buys Shares of 13,302 Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Nuveen Asset Management LLC Has $12.41 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Deutsche Bank AG Buys 7,495 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Bank of America Corp DE Raises Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences amends charter, stockholders vote By Investing.com - Investing.com India
Castle Biosciences Holds Annual Stockholders Meeting - TipRanks
Castle Biosciences amends charter, stockholders vote - Investing.com
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28% - simplywall.st
Castle Biosciences stock hits 52-week low at $15.66 By Investing.com - Investing.com Australia
Scotiabank Issues Pessimistic Forecast for Castle Biosciences (NASDAQ:CSTL) Stock Price - Defense World
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | C - GuruFocus
Castle Biosciences (CSTL) Target Price Updated by Scotiabank | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Price Target Revised by Scotiabank | C - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healt - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference | CSTL Stock News - GuruFocus
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Castle Biosciences Executive Team Reveals Strategic Updates at Jefferies Healthcare Conference - Stock Titan
90,563 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Has $8.42 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Northern Trust Corp Boosts Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Jane Street Group LLC Reduces Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Castle Biosciences Inc Stock (CSTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jun 27 '25 |
Sale |
20.30 |
4,944 |
100,363 |
69,683 |
0.65%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):